Longitudinal Whole-Exome Sequencing Revealed Early Clonal Suppression and Delayed Resistance Evolution in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Ibrutinib (ICBMT 2026) - Oct 8, 2026 - Abstract #OP05-2; Pres time: Sep 18, 2026; 09:10 AM - 09:20 AM; Location: Room A(1F); "Five patients co-enrolled in a prior chlorambucil-obinutuzumab cohort enabled cross-study variant tracking. In this multicenter Korean R/R CLL cohort, 6-month WES captured early treatment-associated clonal suppression but did not reliably distinguish late progressors from sustained responders, who were genomically indistinguishable at both baseline and 6 months despite divergent outcomes. Classical resistance, including PLCG2 mutation, emerged only on extended sequencing, whereas a genomically quiet late profile accompanied durable response. These findings indicate that a single early timepoint is insufficient and support longer-term serial genomic monitoring during continuous BTK inhibitor therapy."
Tumor mutational burden • Whole exome sequencing • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • PLCG2 • TMB
|
|
Ho Cheol Jang 1; Ga-Young Song 1; Hyeonjin Jeong 2; Seung Jung Han 3; Young Hoon Park 4; Ho-Jin Shin 5; Jeong-Ok Lee 6; Ho Sup Lee 7; Ho-Young Yim 8; Deok-Hwan Yang 1
|